17th International Workshop on Pediatrics & HIV 2025
Abstract #15 Efficacy of Second-Line Dolutegravir- versus Boosted Protease Inhibitor-Based ART in Children and Adolescents Living with HIV at 96 and 144 Weeks: Pooled Analysis of the ODYSSEY and CHAPAS-4 Trials - Pauline Amuge
